A Phase I/II Study of the Addition of Ixazomib to ONC201 and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

Trial Profile

A Phase I/II Study of the Addition of Ixazomib to ONC201 and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Apr 2018

At a glance

  • Drugs Dexamethasone (Primary) ; Ixazomib (Primary) ; ONC 201 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 16 Apr 2018 According to the Oncoceutics media release, first patient has been treated in this study.
    • 12 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top